Reuters Examines Increase in Drug Trials Abroad
May 9, 2011
In a special report on global drug trials, Reuters reports that pharmaceutical companies are "seek[ing] cheaper venues for studies and cast[ing] their net further afield for big pools of 'treatment-naive' patients who are not already taking other drugs that could make them unsuitable subjects for testing new ones. ... The drug industry is also paying a lot more attention these days to the promise of emerging markets, whose healthcare authorities, just like those in the United States and Western Europe, are keen to see cutting-edge science conducted in their backyards." The article looks at some of the questions raised as clinical trials increase in areas like Eastern Europe, Asia and Latin America: "Is the quality of the data as reliable as that from a top U.S. medical center? Is it safe to extrapolate common clinical effects from studying patients with different lifestyles and genetic profiles? And are ethical standards in testing new drugs properly upheld in poorer countries?" (Hirschler, 5/6).
President's Bioethics Commission Names International Panel to Review Whether U.S. Rules Protect Clinical Trial Participants in U.S., Abroad
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)